MedPath

MULTICENTRIC, PERSPECTIVE, RANDOMIZED TRIAL TO ASSESS THE INTRAOPERATIVE USE OF HYPERTHERMIC CHEMOTHERAPY IN LOCALLY ADVANCED NON SMALL CELL LUNG CANCER. COMPARISON BETWEEN LOCO-REGIONAL + SYSTEMIC CHEMOTHERAPY VS CONVENTIONAL TREATMENT - HTIPC

Conditions
ON SMALL CELL LUNG CANCER PATIENTS
MedDRA version: 9.1Level: HLTClassification code 10024973Term: Lower respiratory tract neoplasms
Registration Number
EUCTR2007-005980-83-IT
Lead Sponsor
CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

- T2, T3, T4 N0 N1 M0 NON SMALL CELL LUNG CANCER
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- M1, T1
- OTHER NEOPLASTIC DISEASES
- RENAL, HEPATIC, BONE MARROW FAILURE

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: GLOBAL SURVIVAL EVALUATION;Secondary Objective: - DISEASE FREE SURVIVAL<br>- MORTALITY AND MORBIDITY<br>- RISK FACTORS<br>- TOXICITY<br>- POSITIVE PREDICTIVE FACTORS TO LOCO-REGIONAL TREATMENT;Primary end point(s): GLOBAL SURVIVAL EVALUATIO
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath